About Inflammatix
Inflammatix is a company based in San Francisco (United States) founded in 2016.. Inflammatix has raised $191.47 million across 13 funding rounds from investors including NIH, Khosla Ventures and HHS. The company has 54 employees as of December 31, 2020. Inflammatix offers products and services including TriVerity Test and Host Response Dx. Inflammatix operates in a competitive market with competitors including Karius, MeMed, Visby Medical, Agendia and GenMark Diagnostics, among others.
- Headquarter San Francisco, United States
- Employees 54 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$191.47 M (USD)
in 13 rounds
-
Latest Funding Round
$57 M (USD), Series E
Sep 12, 2024
-
Investors
NIH
& 13 more
-
Employee Count
54
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Inflammatix
Inflammatix offers a comprehensive portfolio of products and services, including TriVerity Test and Host Response Dx. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Analyzes immune responses to identify infections and predict severity.
Measures immune signatures for detecting and managing acute infections.
Unlock access to complete
Unlock access to complete
Funding Insights of Inflammatix
Inflammatix has successfully raised a total of $191.47M across 13 strategic funding rounds. The most recent funding activity was a Series E round of $57 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Series E — $57.0M
- First Round First Round
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2024 | Amount | Series E - Inflammatix | Valuation | Think.Health , Khosla Ventures | |
| Jul, 2023 | Amount | Grant - Inflammatix | Valuation |
investors |
|
| Nov, 2021 | Amount | Grant - Inflammatix | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Inflammatix
Inflammatix has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, Khosla Ventures and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech & life sciences focused VC firm investing in geographies such as Europe
|
Founded Year | Domain | Location | |
|
Early-stage startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life sciences & tech sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Inflammatix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Inflammatix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Inflammatix Comparisons
Competitors of Inflammatix
Inflammatix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Karius, MeMed, Visby Medical, Agendia and GenMark Diagnostics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
|
| domain | founded_year | HQ Location |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| domain | founded_year | HQ Location |
Portable PCR diagnostics for infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Genomic diagnostic products for cancer treatment are provided.
|
|
| domain | founded_year | HQ Location |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Inflammatix
Frequently Asked Questions about Inflammatix
When was Inflammatix founded?
Inflammatix was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Inflammatix located?
Inflammatix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Inflammatix a funded company?
Inflammatix is a funded company, having raised a total of $191.47M across 13 funding rounds to date. The company's 1st funding round was a Grant of $12.1M, raised on May 24, 2017.
How many employees does Inflammatix have?
As of Dec 31, 2020, the latest employee count at Inflammatix is 54.
What does Inflammatix do?
Inflammatix was founded in 2016 and is headquartered in San Francisco, United States. Operations focus on the health technology sector, where proprietary technology derived from Stanford University research is utilized. Gene expression patterns in the immune system are measured to diagnose sepsis and acute infections. Products offered include InSep for sepsis testing, ViraBac for infection differentiation, and SARS-CoV-2 swab tests.
Who are the top competitors of Inflammatix?
Inflammatix's top competitors include Visby Medical, MeMed and GenMark Diagnostics.
What products or services does Inflammatix offer?
Inflammatix offers TriVerity Test and Host Response Dx.
Who are Inflammatix's investors?
Inflammatix has 14 investors. Key investors include NIH, Khosla Ventures, HHS, DARPA, and OSF HealthCare.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.